Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more
Yungjin Pharm Co Ltd (003520) - Total Liabilities
Latest total liabilities as of September 2025: ₩156.23 Billion KRW
Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has total liabilities worth ₩156.23 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yungjin Pharm Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Yungjin Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yungjin Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yungjin Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
USA | $64.05 Million |
|
Supermax Corporation Bhd
KLSE:7106
|
Malaysia | RM343.10 Million |
|
Alumil Aluminium Industry S.A
AT:ALMY
|
Greece | €337.09 Million |
|
PCA Corporation
PINK:PCRDF
|
USA | $14.95 Billion |
|
WAWEL SA
WAR:WWL
|
Poland | zł116.87 Million |
|
China Boton Group Company Limited
PINK:CHBGF
|
USA | $2.90 Billion |
|
Profile Systems & Software SA
AT:PROF
|
Greece | €36.07 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Yungjin Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yungjin Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yungjin Pharm Co Ltd (2013–2024)
The table below shows the annual total liabilities of Yungjin Pharm Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩144.45 Billion | +5.47% |
| 2023-12-31 | ₩136.97 Billion | +20.98% |
| 2022-12-31 | ₩113.21 Billion | +26.91% |
| 2021-12-31 | ₩89.21 Billion | +21.10% |
| 2020-12-31 | ₩73.67 Billion | -13.02% |
| 2019-12-31 | ₩84.69 Billion | +0.22% |
| 2018-12-31 | ₩84.51 Billion | +0.37% |
| 2017-12-31 | ₩84.20 Billion | -9.65% |
| 2016-12-31 | ₩93.19 Billion | -0.09% |
| 2015-12-31 | ₩93.27 Billion | +19.30% |
| 2014-12-31 | ₩78.18 Billion | +16.88% |
| 2013-12-31 | ₩66.89 Billion | -- |